Two other potentially important questions not addressed in this analysis are the effect of the cell dose 5 and the effect of the administration of myeloid growth factors early after transplantation. 6 ...
The effects of immunosuppressive regimens on the outcomes of patients with hematological malignancies undergoing allogeneic stem cell transplantation remain uncertain. We conducted an individual ...
The Pharmacovigilance Risk Assessment Committee initially recommended new measures in July. The European Medicines Agency (EMA) has recommended new measures to prevent serious and potentially fatal ...
High dose chemotherapy with peripheral blood stem cell (P.B.S.C.) rescue in metastatic Ewing’s sarcoma at diagnosis No significant financial relationships to disclose. This is an ASCO Meeting Abstract ...
The American College of Rheumatology (ACR) has issued new guidelines on the treatment of rheumatoid arthritis, addressing questions about initial treatment with methotrexate and minimizing reliance on ...
Disease-modifying drug therapies are being sought intensively for osteoarthritis (OA), but none have proved out thus far. A previous trial in patients with OA of the hand had found that methotrexate ...
Methotrexate falls into the category of disease-modifying antirheumatic drugs, or DMARDs. These drugs do more than deal with symptoms; they actually slow down progression of the disease. About 60 ...
Shorla Oncology ('Shorla'), a U.S.-Ireland specialty pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has expanded the approval of JYLAMVO (methotrexate)to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback